DESIGN THERAPEUTICS INC. - COMMON STOCK

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

13 11 2024 07:00:49 提供 Nasdaq GlobeNewswire

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

07 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

05 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

08 5 2024 15:05:01 提供 Nasdaq GlobeNewswire

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

07 5 2024 05:30:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

19 3 2024 15:01:00 提供 Nasdaq GlobeNewswire

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

12 3 2024 05:30:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

13 11 2023 15:05:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

14 8 2023 15:05:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

14 8 2023 15:01:00 提供 Nasdaq GlobeNewswire

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

31 5 2023 05:30:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

09 5 2023 15:05:01 提供 Nasdaq GlobeNewswire

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

24 4 2023 05:30:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

14 3 2023 15:05:00 提供 Nasdaq GlobeNewswire

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

08 2 2023 05:30:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

07 12 2022 15:01:00 提供 Nasdaq GlobeNewswire

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

03 11 2022 15:05:02 提供 Nasdaq GlobeNewswire

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

17 10 2022 15:05:00 提供 Nasdaq GlobeNewswire

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

22 9 2022 05:30:00 提供 Nasdaq GlobeNewswire